Amlodipine and valsartan as components of a rational and effective fixed-dose combination.

Détails

Ressource 1Télécharger: BIB_F0D25C6C63EC.P001.pdf (215.12 [Ko])
Etat: Serval
Version: de l'auteur
ID Serval
serval:BIB_F0D25C6C63EC
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Amlodipine and valsartan as components of a rational and effective fixed-dose combination.
Périodique
Vascular Health and Risk Management
Auteur(s)
Waeber B., Ruilope L.M.
ISSN
1178-2048[electronic]
Statut éditorial
Publié
Date de publication
2009
Volume
5
Numéro
1
Pages
165-174
Langue
anglais
Notes
Publication types: Journal Article ; Review
Résumé
Pharmacological treatment of hypertension is effective in preventing cardiovascular and renal complications. Calcium antagonists and blockers of the renin-angiotensin system are widely used today to initiate antihypertensive therapy but, when given as monotherapy, do not suffice in most patients to normalize blood pressure. Combining the two types of agents considerably increases the antihypertensive efficacy, but not at the expense of a deterioration of tolerability. This is exemplified by the experience accumulated with the recently developed fixed dose combination containing the AT(1)-receptor blocker valsartan (160 mg) and the dihydropyridine amlodipine (5 or 10 mg). In a randomized trial, an 8-week treatment normalized blood pressure (<140/90 mmHg) within 8 weeks in a large fraction of hypertensive patients (78.4% and 85.2% using the 5/160 [n = 371] and 10/160 mg [n = 377] dosage, respectively). Like all AT(1)-receptor blockers valsartan has a placebo-like tolerability. Valsartan prevents to a large extent the occurrence amlodipine-induced peripheral edema. Both amlodipine and valsartan have beneficial effects on cardiovascular morbidity and mortality, as well as protective effects on renal function. The co-administration of these two agents is therefore very attractive, as it enables a rapid and sustained blood pressure control in hypertensive patients. The availability of a fixed-dose combination based on amlodipine and valsartan is expected therefore to facilitate the management of hypertension, to improve long-term adherence with antihypertensive therapy and, ultimately, to have a positive impact on cardiovascular and renal outcomes.
Mots-clé
Age Factors, Aged, Amlodipine/adverse effects, Amlodipine/therapeutic use, Angiotensin II Type 1 Receptor Blockers/adverse effects, Angiotensin II Type 1 Receptor Blockers/therapeutic use, Antihypertensive Agents/therapeutic use, Blood Pressure/drug effects, Calcium Channel Blockers/adverse effects, Calcium Channel Blockers/therapeutic use, Diuretics/therapeutic use, Drug Combinations, Humans, Hypertension/drug therapy, Hypertension/physiopathology, Medication Adherence, Middle Aged, Tetrazoles/adverse effects, Tetrazoles/therapeutic use, Treatment Outcome
Pubmed
Création de la notice
02/09/2009 9:34
Dernière modification de la notice
03/03/2018 22:37
Données d'usage